Evidence map›Paper›PMID 30085297›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2019

Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression.

Austin Gonzalez, Richard Krieg, Hugh D Massey, Daniel Carl, Shobha Ghosh, Todd W B Gehr, Siddhartha S Ghosh

Open access · hybridAbstract read
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 184 citations in OpenAlex.

  1. Frontiers in immunology · 2022
    Trial
  2. Trial
  3. Review
  4. Review
  5. The gut-heart axis in cardio-oncology.Cardiovascular research · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Pediatric and adult point of view on the gut-kidney axis in CKD.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Austin GonzalezDepartment of Internal Medicine, Nephrology, Virginia Commonwealth University, Richmond, VA, USA.
Richard KriegDepartment of Anatomy, Virginia Commonwealth University, Richmond, VA, USA.
Hugh D MasseyDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, USA.
Daniel CarlDepartment of Internal Medicine, Nephrology, Virginia Commonwealth University, Richmond, VA, USA.
Shobha GhoshDepartment of Internal Medicine, Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
Todd W B GehrDepartment of Internal Medicine, Nephrology, Virginia Commonwealth University, Richmond, VA, USA.
Siddhartha S GhoshDepartment of Internal Medicine, Nephrology, Virginia Commonwealth University, Richmond, VA, USA.
Virginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe associated increase in the lipopolysaccharide (LPS) levels and uremic toxins in chronic kidney disease (CKD) has shifted the way we focus on intestinal microbiota. This study shows that a disruption of the intestinal barrier in CKD promotes leakage of LPS from the gut, subsequently decreasing insulin sensitivity. Butyrate treatment improved the intestinal barrier function by increasing colonic mucin and tight junction (TJ) proteins. This modulation further ameliorated metabolic functions such as insulin intolerance and improved renal function.

methodsRenal failure was induced by 5/6th nephrectomy (Nx) in rats. A group of Nx and control rats received sodium butyrate in drinking water. The Nx groups were compared with sham-operated controls.

resultsThe Nx rats had significant increases in serum creatinine, urea and proteinuria. These animals had impaired glucose and insulin tolerance and increased gluconeogenesis, which corresponded with decreased glucagon-like peptide-1 (GLP-1) secretion. The Nx animals suffered significant loss of intestinal TJ proteins, colonic mucin and mucin 2 protein. This was associated with a significant increase in circulating LPS, suggesting a leaky gut phenomenon. 5'adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, known to modulate epithelial TJs and glucose metabolism, was significantly reduced in the intestine of the Nx group. Anti-inflammatory cytokine, interleukin 10, anti-bacterial peptide and cathelicidin-related antimicrobial peptide were also lowered in the Nx cohort. Butyrate treatment increased AMPK phosphorylation, improved renal function and controlled hyperglycemia.

conclusionsButyrate improves AMPK phosphorylation, increases GLP-1 secretion and promotes colonic mucin and TJ proteins, which strengthen the gut wall. This decreases LPS leakage and inflammation. Taken together, butyrate improves metabolic parameters such as insulin resistance and markers of renal failure in CKD animals.

Indexed as

AnimalsButyric AcidDisease Models, AnimalHistamine AntagonistsImmunohistochemistryInsulin ResistanceIntestinal MucosaMaleMucinsPermeabilityRatsRenal Insufficiency, ChronicButyric AcidHistamine AntagonistsMucinschronic renal failurediabetic kidney diseasegutnephrectomyshort chain fatty acid

Identifiers

PMID30085297
PMCPMC6503301
OpenAlexW2945333360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.